Stocktoria
20/20 Biolabs, Inc. AIDX
Nasdaq · XNAS · stock · Services-Testing Laboratories · website · IPO 2021-09-08
20/20 Biolabs, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | $2.0M | $1.8M |
| Gross profit | $604,541 | $360,311 |
| R&D expense | $592,569 | $1.3M |
| SG&A expense | $3.3M | $4.8M |
| Operating income | -$3.3M | -$5.7M |
| Net income | -$3.7M | -$5.6M |
| EPS (diluted) | $-0.76 | $-1.16 |
| Operating cash flow | -$1.9M | -$2.6M |
| Cash & equivalents | $1.0M | $1.8M |
| Inventory | $116,217 | $47,164 |
| Total assets | $4.1M | $3.6M |
| Total liabilities | $4.2M | $2.1M |
| Shareholders' equity | -$19,225 | $1.5M |
Source: SEC EDGAR filings · CIK 0001139685 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.